Suchergebnisse

Land grabbing has transformed rural environments across the global South, generating resistance or political reactions "from below". In authoritarian countries like Laos, where resource investments are coercively developed and insulated from political dissent, resistance appears absent at first glance. Yet, it is occurring under the radar, largely outside transnational activist networks. In this article, we examine how resistance can protect access to rural lands in contexts where it is heavily repressed. Resistance here occurs with, rather than against the state by foregrounding the contradictions of land use and ownership within state spaces, such as competing goals of large-scale industrial plantations versus smallholder agriculture and national forest conservation. Such contradictions are engaged by using historical, place-based political connections to exploit the scalar frictions of a fragmented state and occupying plantation clearance sites to highlight contested lands in situ. Nonetheless, such strategies remain spatially and socially uneven amongst the Lao peasantry.

Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use. ; Development of this roadmap received support from Cancer Research UK and the Engineering and Physical Sciences Research Council (grant references A/15267, A/16463, A/16464, A/16465, A/16466 and A/18097), the EORTC Cancer Research Fund, and the Innovative Medicines Initiative Joint Undertaking (grant agreement number 115151), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in kind contribution. ; Peer-reviewed ; Publisher Version